The CIN or MSS pathways are characterized by the accumulation of a characteristic set of mutations in specific oncogenes (BRAF, KRAS, PI3K) and tumor-suppressor genes (APC, TP53), leading to numerical and structural chromosomal aberrations and a high frequency of loss of heterozygosity [11]. Here, TP53 is linked to neoplasm.